Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

